Related Experiment Video
Updated: May 20, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Lowering of amyloid beta peptide production with a small molecule inhibitor of amyloid-β precursor protein
Pauline Pl So1, Ella Zeldich, Kathleen I Seyb
1Department of Medicine Graduate Program in Molecular Medicine, Boston University School of Medicine, Boston, MA, USA.
Abstract:
The amyloid β precursor protein (APP) is a single-pass transmembrane glycoprotein that is ubiquitously expressed in many cell types, including neurons. Amyloidogenic processing of APP by β- and γ-secretases leads to the production of amyloid-β (Aβ) peptides that can oligomerize and aggregate into amyloid plaques, a characteristic hallmark of Alzheimer's disease (AD) brains. Multiple reports suggest that dimerization of APP may play a role in Aβ production; however, it is not yet clear whether APP dimers increase or decrease Aβ and the mechanism is not fully understood. To better understand the relationship between APP dimerization and production of Aβ, a high throughput screen for small molecule modulators of APP dimerization was conducted using APP-Firefly luciferase enzyme complementation to detect APP dimerization. Selected modulators identified from a compound library of 77,440 compounds were tested for their effects on Aβ generation. Two molecules that inhibited APP dimerization produced a reduction in Aβ levels as measured by ELISA. The inhibitors did not change sAPPα or γ-CTF levels, but lowered sAPPβ levels, suggesting that blocking the dimerization is preventing the cleavage by β-secretase in the amyloidogenic processing of APP. To our knowledge, this is the first High Throughput Screen (HTS) effort to identify small molecule modulators of APP dimerization. Inhibition of APP dimerization has previously been suggested as a therapeutic target in AD. The findings reported here further support that modulation of APP dimerization may be a viable means of reducing the production of Aβ.
Insights
Researchers screened compounds to find molecules that inhibit amyloid precursor protein (APP) dimerization. Two inhibitors reduced amyloid-beta (Aβ) production, suggesting APP dimerization modulation as a potential Alzheimer's disease therapy.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Alzheimer's disease (AD) is characterized by amyloid plaques formed from amyloid-beta (Aβ) peptides.
- Amyloid precursor protein (APP) processing is central to Aβ production.
- The role of APP dimerization in Aβ generation remains unclear.
Purpose of the Study:
- To identify small molecules that modulate APP dimerization.
- To investigate the impact of APP dimerization on Aβ production.
Main Methods:
- High-throughput screening (HTS) using APP-Firefly luciferase complementation assay.
- Testing identified modulators for effects on Aβ generation via ELISA.
- Analysis of sAPPα, sAPPβ, and γ-CTF levels.
Main Results:
- Identified two small molecules that inhibit APP dimerization.
- These inhibitors reduced Aβ levels without altering sAPPα or γ-CTF.
- Inhibitors lowered sAPPβ levels, indicating reduced β-secretase cleavage.
Conclusions:
- This is the first HTS for small molecule modulators of APP dimerization.
- Inhibition of APP dimerization reduces Aβ production.
- Modulating APP dimerization is a potential therapeutic strategy for Alzheimer's disease.
Related Concept Videos
Alzheimer's Disease: Treatment
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

